Name | (3R)-5,7-Dihydroxy-6-methyl-3-(4'-hydroxybenzyl)chroman-4-one |
---|
Description | LPRP-Et-97543 is a potent anti-HBV agent. LPRP-Et-97543 reduces Core, S, and preS but not X promoter activities. LPRP-Et-97543 can be used for acute and chronic HBV infections research[1]. |
---|---|
Related Catalog | |
In Vitro | LPRP-Et-97543 (0.625-40 μg/ml; 3 days) causes cytotoxic effects at doses >10 μg/ml in HepG2.2.15 and HBV-transfected Huh7 cells[1]. LPRP-Et-97543 (2.5-10 μg/ml; 3 days) has inhibitory effects on HBsAg and HBeAg secretions. And the HBeAg inhibition rate is higher than the HBsAg inhibition rate in HepG2.2.15 cells[2]. LPRP-Et-97543 (2.5-10 μg/ml; 2 days after transfected with pHBV1.2 plasmid for 2 days) significantly reduces both precore/pregenomic and major S/preS RNA with the LPRP-Et-97543 inhibition potential higher on surface RNA than on the precore/pregenomic RNA[2]. LPRP-Et-97543 (2.5-10 μg/ml; 2 days after transfected with pHBV1.2 plasmid for 2 days) potently reduces intracellular LHBsAg and HBcAg protein levels compared to vehicle controls. Additionally, LPRP-Et-97543 potently inhibits the replication HBV DNAlevel in HBV transfected Huh7 cells[2]. LPRP-Et-97543 (2.5-10 μg/ml; 2 days after transfected with pHBV1.2 plasmid for 2 days) reduces nuclear p65/p50 NF-κB protein expression and reduces phosphorylated NF-κBp65 in Huh7 cells[2]. Western Blot Analysis[1] Cell Line: Huh7 cells with or without pHBV1.2 Concentration: 2.5-10 μg/ml Incubation Time: 2 days Result: Decreased nuclear and nuclear p-p65 expression and increased cytoplasmic IκBα expression. |
References |
Molecular Formula | C17H16O5 |
---|---|
Molecular Weight | 300.3 |
Exact Mass | 300.099774 |